(NASDAQ: RPTX) Repare Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.82%.
Repare Therapeutics's earnings in 2025 is -$72,200,000.On average, 3 Wall Street analysts forecast RPTX's earnings for 2025 to be -$61,736,141, with the lowest RPTX earnings forecast at -$59,311,745, and the highest RPTX earnings forecast at -$63,550,140. On average, 4 Wall Street analysts forecast RPTX's earnings for 2026 to be -$47,396,093, with the lowest RPTX earnings forecast at -$53,078,810, and the highest RPTX earnings forecast at -$40,711,809.
In 2027, RPTX is forecast to generate -$70,371,980 in earnings, with the lowest earnings forecast at -$67,612,294 and the highest earnings forecast at -$72,443,893.